Annual report pursuant to Section 13 and 15(d)

Note 16 - Segment Information

v3.7.0.1
Note 16 - Segment Information
12 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
16.
Segment Information
 
The accounting policies followed by the Company's molecular diagnostics business are described in Note
1,
Nature of Business and Significant Accounting Policies.
 
Effective
December
 
31,
2015,
the Company has
one
reporting segment: the Company's molecular diagnostics business, after the divestiture of its CSO business on
December
22,
2015.
The Company realigned its reporting segments due to the integration of RedPath and acquiring certain assets from Asuragen, to reflect the Company's current and going forward business strategy. The Company's current reporting segment structure is reflective of the way the Company's management views the business, makes operating decisions and assesses performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.
 
The Company's molecular diagnostics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company's molecular diagnostics business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are principally focused on early detection of high potential progressors to cancer. Customers in the Company's molecular diagnostics segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through
one
centrally managed marketing group and the chief operating decision maker views their results on a combined basis.